Objective-To characterise the natural history of sexually transmitted HIV-I infection in homosexual and bisexual men.
Introduction
The proportion of people infected with HIV-I who will eventually develop life threatening diseases such as AIDS or AIDS related complex is not completely understood.' Risk of progression from HIV-I infection to AIDS has been prospectively studied in cohorts of homosexual and bisexual men,26 parenteral drug users,2 7 8 transfusion recipients,9 '°people with haemophilia,29 "-'9 and vertically infected infants. '4 16 Whereas studies of transfusion recipients, haemophiliac patients, and vertically infected infants have been able to determine the approximate dates of HIV-I seroconversion and therefore the duration of HIV-I infection, studies of sexually transmitted HIV-I infection in homosexual and bisexual men have generally been conducted in men who were already infected with HIV-I at the time of their recruitment. Thus most of these studies have been unable to examine the long term risk of progression from infection to AIDS as a function of duration of HIV-I infection.
To understand better the relation between duration of HIV-I infection and the risk of progressing to AIDS we have expanded our longitudinal cohort study of homosexual and bisexual men.'7-2' We now report the risk of AIDS in men who have been infected for up to 12 years.
Methods

BACKGROUND
The San Francisco City Clinic cohort was comprised of 6705 men who were recruited from San Francisco City Clinic, the municipal sexually transmitted disease clinic, for studies of the incidence and prevalence of sexually transmitted hepatitis B from 1978 to 1980 . At the time of their recruitment these men were 18 years of age or older and had a history of sexual contact with other men. Details of these original hepatitis B studies have been published previously.2223
The first 831 participants were consecutively enrolled from January through May 1978 in a cross sectional study of the prevalence of hepatitis B virus infection. All were interviewed regarding risk factors for this infection. Among the 831 men, 74 (9%) were negative for seromarkers (HBsAg, HBsAb, HBcAb).
An additional 5874 men were tested for seromarkers and, if they had no evidence of infection, were asked to participate in a prospective study of the incidence of hepatitis B and to be interviewed and retested at three intervals of four months; 1639 (28%) seronegative men agreed to participate in this incidence study.
In 1980-1 a sample of 359 (21%) of the participants who were negative for all hepatitis B virus markers in the prevalence (n=34) and incidence (n=325) studies was recruited into a multicenter, randomised double blind trial of plasma derived hepatitis B vaccine; they had serum drawn about every six months. All unused serum samples from the initial screening, the prevalence and incidence studies, and the vaccine trial were frozen and stored.
In 1981 the first cases of Kaposi's sarcoma and Pneumocystis carinii pneumonia were reported in homosexual men. 24 AIDS was determined by history and physical examination or by cross matching with San Francisco and national AIDS surveillance registries by date of birth and soundex codes (an alphanumeric code based on last name). Deaths were determined through AIDS surveillance data, by direct report, and through cross matches with San Francisco vital statistics records and the National Death Index. AIDS related complex, asymptomatic generalised lymphadenopathy, and the absence ofclinical signs or symptoms ofHIV-I infection were determined by history and physical examination. 17 In addition to cross matching AIDS surveillance registries and death records for participants followed prospectively, we also cross matched these records for all cohort members. We attempted to confirm computer generated matches by contacting the cohort member identified as a possible case or by contacting the source of the report if the participant was known to have died. As described above, participants known to have died before they could be asked to participate in the study had their stored serum samples tested for HIV 14 2 909(55) 12 9 HBVVaccineTrial) 309(86) 13 9 50 (14) 12-0 *Cumulative AIDS cases per 100 participants.
tPositive for any marker of hepatitis B virus infection (HBsAg, HBsAb, HBcAb) on entry into study. tNegative for markers on entry into study.
534 Participants from the prevalence studs! and 325 from the incidence study were enrolled in the vaccine trial. To further define the relation between duration of HIV-I infection and disease progression we included data from all 489 men with well characterised dates of seroconversion in a Kaplan-Meier curve of the cumulative proportion of men with AIDS by estimated duration of infection. Of these 489 men, 226 (46%) had been diagnosed as having AIDS. 
Discussion
Of the men in this study whom we estimated to have seroconverted to HIV-I from 1977 to 1980, 81% had signs or symptoms of HIV-I infection or had died of AIDS. Over time, there has been a gradual decline in the proportion of infected men who remain clinically well and an increase in the proportion with AIDS and other clinical manifestations ofHIV-I infection. Among men who have developed AIDS, our analysis shows that the likelihood of developing AIDS is directly related to the duration of HIV-I infection. This risk increases over time, with an estimated cumulative incidence of AIDS of 54% (49% to 59%) 11 years after seroconversion.
There are, however, at least five potential sources of systematic error in this study. Firstly, cohort members were originally recruited from a sexually transmitted disease clinic, and if repeated venereal infections or reexposure to HIV-I are important in the development of AIDS and the other clinical manifestations of HIV-I infection,3034 these men may be at higher risk of clinical disease than a randomly selected population of homosexual and bisexual men infected with HIV-I. This would limit the populations to which our results should be generalised. For example, some laboratory studies have suggested that coinfection with cytomegalovirus or herpes simplex virus enhances HIV-I replication.30"3 Arguing against this is our finding that the cumulative risk of AIDS among men who participated in our hepatitis B virus trials and who had therefore never been infected with hepatitis B, a sexually transmitted disease of homosexual and bisexual men, did not differ from the risk for other men in the cohort (72% of whom had markers of previous or current hepatitis B infection at the time ofrecruitment). Additionally, our cumulative risk ofAIDS by estimated duration of HIV-I infection is lower than that reported from other seroincident cohorts of homosexual and bisexual men infected with HIV-I. For example, the risk ofAIDS was 9*6% after 30 months in an Amsterdam cohort of homosexual and bisexual men. 6 Similarly, the five year risk of AIDS was estimated to be 22% (16% to 25%) in the multicenter AIDS collaborative study4 and 23% (22% to 24%) in the National Cancer Institute registry of homosexual male HIV-I seroconverters35 (R J Biggar, personal communication). In our cohort, the corresponding observed risks of AIDS were 3% (1% to 5%) three years after seroconversion and 13% (10% to 16%) five years after seroconversion.
Secondly Lastly, our modelling of seroconversion dates of men who were seropositive on entry into the study may have led to overestimation or underestimation of the risk of clinical disease,4 but previous analysis of subjects in this cohort who seroconverted suggested that the first seroconversions occurred in 1977.' Additionally, we found no difference in risk of progression between men seropositive on entry and those who seroconverted.
Comparable data for the risk of clinical disease after more than five years of HIV-I infection are not available from other cohorts of homosexual and bisexual men. The cumulative risk of AIDS has been reported to be 49% (36% to 62%) seven years after HIV-I infection (rather than seroconversion) for transfusion recipients'0 and 25 1% (20-3% to 29 9%) nine years after seroconversion for people with haemophilia. '3 Differences in routes of transmssion, in inoculum sizes, and probably in underlying host immunity may limit the direct comparablility of these types of cohorts to cohorts of homosexual and bisexual men infected through sexual intercourse.
In out analysis we estimated time from seroconversion to diagnosis of AIDS rather than time from HIV-I infection to diagnosis of AIDS. Although most people seem to develop detectable antibody to HIV-I within a few months after infection, there have been reports of people who took six months or more to develop a diagnostic antibody response, suggesting the possibility of HIV-I infection months to years before the appearance of a positive test result. 4648 We have previously published studies evaluating specimens negative for HIV-I antibody by using polymerase chain reaction techniques; these studies suggest that this phenomenon, if it occurred, was extremely unusual in this cohort.493' Models of the time from detecting HIV DNA by the polymerase chain reaction to detecting HIV antibody estimated a median duration of 2-4 months; the time after which 95% of cases would be predicted to have seroconverted was estimated to be 10 3 months.3' Therefore, the possibility of long periods of HIV infection before seroconversion in our cohort seems very low.
The likelihood of eventually developing AIDS after HIV-I infection remains unknown. The 
Patients and methods
We analysed prospectively 108 consecutive patients who presented to our combined gastroenterology service over three years in whom abdominal ultrasound scanning confirmed the presence of a clinically or radiologically suspected mass or identified a previously undetected discrete mass. In many cases malignancy was suspected and it was important to confirm or exclude the presence of disseminated disease. Thirty two patients underwent percutaneous biopsy, guided by ultrasound, of lesions of the liver. In 13 patients with hepatomegaly ultrasound scanning showed single (seven) or multiple (six) lesions. Eleven patients with proved malignant disease were scanned to exclude liver metastases. In eight patients ultrasound scanning was performed to investigate non-specific abdominal symptoms.
Twenty patients underwent biopsy of abdominal or retroperitoneal lesions. Six had a palpable abdominal mass, and two presented with abdominal pain but had no abnormalities on examination or on contrast radiological examination. Six patients underwent biopsy of para-aortic or retroperitoneal lymph nodes, of whom two had received treatment for lymphoma. Three patients with abnormal results of liver function tests had portal lymphadenopathy on ultrasound examination. Two patients underwent biopsy of the pylorus after equivocal findings on endoscopy and radiological examination. One patient in whom the result of endoscopic retrograde cholangiopancreatography was equivocal had a lesion identified in the choledochojejunal anastomosis from a previous Whipple's operation. All but six of this group had other extensive investigations before ultrasound scanning identified a mass.
Ten patients underwent biopsy of renal masses; in six these were an incidental finding at intravenous urography. Two 
